Nexstim Plc launches NBT® system for depression at the US Clinical TMS Society Annual Meeting in New York
Helsinki, Finland: 9 May 2018 – Nexstim Plc (NXTMH:HEX, NXTMS:STO) the targeted neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic application, announces that it is launching its Navigated Brain Therapy (NBT®) system in the US for the treatment of Major Depressive Disorder (MDD) at the Clinical TMS (transcranial magnetic stimulation) Society Annual Meeting in New York following FDA clearance for the device in November last year.
The Clinical TMS Society Annual Meeting takes place from 11-13 May, and is a focused conference, bringing together over 500 participants including current and new TMS practitioners. Nexstim will introduce and demonstrate the use of its NBT® system at the event and will also participate in a PULSES workshop session to train physicians in the use of the system to treat depression.
More info on Nexstim’s website.